Bayer stock slips as stronger Pharma outlook meets litigation costs
Published on 11/09/2026 at 11:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth and guidance take focus
- Third-quarter sales and adjusted EBITDA increased, led by Pharmaceuticals.
- Bayer raised its 2026 adjusted EBITDA, free cash flow and net debt outlook.
- Litigation payments continued to weigh on cash generation despite the operational improvement.
Bayer reported stronger-than-expected operational momentum in its Pharmaceuticals division on November 3 and raised several full-year 2026 targets. The company said group sales increased 4.1 percent to 10.053 billion euros in the third quarter, while EBITDA before special items rose 6.9 percent to 1.615 billion euros. Bayer stock traded at 55.54 euros on Lang & Schwarz at 10:52 CET on Monday, November 9, 2026, 0.07 percent below the Xetra close of Friday, November 6.
The results and revised outlook were published in Bayer's third-quarter release. On a currency- and portfolio-adjusted basis, group sales increased 1.9 percent. Bayer said the positive currency effect contributed 246 million euros to sales and 36 million euros to EBITDA before special items.
Pharmaceuticals leads the improvement
Pharmaceuticals was the main growth engine. Division sales rose 8.0 percent to 4.680 billion euros on a reported basis and 6.4 percent after currency and portfolio adjustments. EBITDA before special items increased 23.6 percent to 1.292 billion euros, lifting the division's margin before special items by 3.5 percentage points to 27.6 percent.
Bayer highlighted continued momentum from Nubeqa and Kerendia. At the same time, the company said established products Xarelto and Eylea continued to decline as expected. Crop Science posted lower sales and earnings in the seasonally smaller quarter, while Consumer Health held sales at the prior-year level but reported lower earnings.
Higher targets, persistent cash pressure
Management raised the 2026 Pharmaceuticals EBITDA margin outlook to between 25 and 27 percent, from 23 to 25 percent previously. Group EBITDA before special items is now expected between 9.8 billion euros and 10.3 billion euros on a currency-adjusted basis, compared with the former range of 9.6 billion euros to 10.1 billion euros.
The free cash flow forecast improved by 1.0 billion euros to between minus 1.5 billion euros and minus 0.5 billion euros. Bayer also lowered its expected year-end net financial debt range to 28.0 billion euros to 29.0 billion euros, from 29.0 billion euros to 30.0 billion euros. The changes indicate that management expects the stronger Pharmaceuticals performance to offset pressure elsewhere in the group.
Cash generation nevertheless remained a central investor concern. Third-quarter free cash flow was negative 293 million euros, compared with positive 596 million euros a year earlier. Bayer attributed part of the deterioration to higher payments related to legal proceedings. The company also reported a net loss of 672 million euros for the quarter, narrower than the loss of 963 million euros in the prior-year period.
Litigation remains a key risk
In its results materials, Bayer said litigation-related payments continued to affect cash flow and discussed its efforts to contain Roundup-related legal exposure. The company also said it secured a favorable jury decision in the first glyphosate case to go to trial since the U.S. Supreme Court's June ruling. The legal developments remain relevant to the balance sheet even as Pharmaceuticals improves operating performance.
For investors, the revised targets strengthen the case that Pharmaceuticals can support group earnings during a period of portfolio and legal pressure. The contrast between higher adjusted earnings guidance and still-negative free cash flow keeps execution, litigation payments and debt reduction central to the stock's outlook.
The real-time quote of Bayer stock provides the current Lang & Schwarz indication, while the next major company update will show whether the upgraded targets remain on track.
The DAX provides the relevant German market setting for Bayer stock; current DAX market reports track the wider index environment.
More company-specific developments are collected in more news and analyses on Bayer stock.
Bayer stock at a glance
- Company: Bayer AG
- ISIN: DE000BAY0017
- Ticker: BAYN.DE
- Home exchange: Xetra
- Lang & Schwarz quote: 55.54 euros at 10:52 CET on November 9, 2026
- Change versus Xetra close: 0.07 percent lower than 55.58 euros on November 6, 2026
